LOAd 703

Drug Profile

LOAd 703

Alternative Names: LOAd703

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lokon Pharma
  • Developer Lokon Pharma; Uppsala University
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Dendritic cell stimulants; Macrophage stimulants; Natural killer cell stimulants; T-cell receptor gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Biliary cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 01 Mar 2018 Phase-I/II clinical trials in Biliary cancer (Adjunctive treatment, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Sweden (Intratumoural) (NCT03225989)
  • 01 Mar 2018 Phase-I/II clinical trials in Colorectal cancer (Adjunctive treatment, Second-line therapy or greater, Metastatic disease, Late-stage disease) in Sweden (Intratumoural) (NCT03225989)
  • 01 Mar 2018 Phase-I/II clinical trials in Ovarian cancer (Adjunctive treatment, Late-stage disease) in Sweden (Intratumoural) (NCT03225989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top